Systematic lupus erythematosus

Systematic lupus erythematosus

  • April 2016 •
  • 190 pages •
  • Report ID: 4035420 •
  • Format: PDF
Datamonitor Healthcare forecasts a shift in the systemic lupus erythematosus (SLE) market over the next 10 years, as new product approvals drive a movement from traditional off-label treatment to prescribing of approved therapies.

This report addresses the following questions:

- How has the approval of Benlysta impacted the treatment algorithm and clinical trial design?
- What will drive growth in the SLE market over the next 10 years, and which patient groups will be most impacted by new product launches?
- What factors have led to the late-phase clinical trial failures that continue to be seen in SLE?
- Which clinical attributes will a new drug need to demonstrate in order to compete in this market?
Loading...

We are very sorry, but an error occurred.
Please contact support@reportbuyer.com if the problem remains.